Castleman disease · 9 regimens
Cost vs Efficacy · 2 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Siltuximab monotherapy Variant #01 | — | R 75 219 | 21d | — | — | — | — | — |
Tocilizumab monotherapy Variant #01 | — | R 9 664 | 14d | — | — | — | — | — |
Bortezomib monotherapy Variant #14 | — | R 8 539 | 35d | ~30.3 mo | — | ~27 | ~R 230 565 PFS proxy · indirect | 5 |
TCP Variant #01 | — | R 2 162 | 7d | — | — | — | — | — |
Cyclosporine monotherapy Variant #03 | — | R 2 156 | — | — | — | — | — | — |
Sirolimus monotherapy Variant #01 | — | R 459 | — | — | — | — | — | — |
Rituximab monotherapy N/A - secondary systemic drug | — | R 52 | 180d | ~20.3 mo | — | ~4 | ~R 208 PFS proxy · indirect | 20 |
Anakinra monotherapy Variant #01 Partial | — | — | 28d | — | — | — | — | — |
Placebo Partial | — | — | — | ~4.2 mo | ~8.0 mo | — | — | 145 |
9 of 9 regimens shown